Medtech deal diligence must be designed to surface anti-corruption exposure across jurisdictions to incorporate that risk into deal structure. Integration must then prevent schemes from emerging post-close—when earnouts are done but liability risk is not.Read More
DOJ Bribery Declination Offers Blueprint for Global Medtech M&A
